|
Originally published In Press as doi:10.1074/jbc.M104913200 on August 3, 2001
J. Biol. Chem., Vol. 276, Issue 44, 41143-41149, November 2, 2001
Induction of the Transcriptional Repressor Yin
Yang-1 by Vascular Cell Injury
AUTOCRINE/PARACRINE ROLE OF ENDOGENOUS FIBROBLAST GROWTH
FACTOR-2*
Fernando S.
Santiago §,
Harry C.
Lowe §,
Yuri V.
Bobryshev¶, and
Levon M.
Khachigian §
From the ¶ Surgical Professorial Unit, St. Vincent's Hospital
and the Center for Thrombosis and Vascular Research, The
University of New South Wales and the § Department of
Haematology, The Prince of Wales Hospital, Sydney, New South
Wales 2052, Australia
Received for publication, May 29, 2001, and in revised form, July 9, 2001
 |
ABSTRACT |
Yin Yang-1 (YY1) is a multifunctional
transcription factor that can repress the expression of many growth
factor, hormone, and cytokine genes implicated in atherogenesis. YY1
expression is activated in rat vascular smooth muscle cells shortly
after injury. YY1 DNA binding activity paralleled elevated protein
levels in the nucleus. Smooth muscle cell injury triggered the rapid extracellular release of immunoreactive fibroblast growth factor-2 (FGF-2). YY1 induction after injury was blocked by neutralizing antibodies directed against FGF-2. This growth factor increased YY1
mRNA and protein expression and stimulated YY1 binding and transcriptional activity. Overexpression of YY1 inhibited smooth muscle
cell replication. Immunohistochemical analysis demonstrated YY1
staining in medial smooth muscle cells, coincident with FGF-2 expression. Proliferating cell nuclear antigen staining, in
contrast, was confined mainly to the atherosclerotic intima. This is
the first demonstration that YY1 is induced by either injury or FGF-2, is differentially expressed in normal and diseased human arteries, and
that its overexpression inhibits vascular smooth muscle but not
endothelial cell replication.
 |
INTRODUCTION |
Yin Yang-1 (YY1;1 also
called NF-E1, , or UCRBP) is a GLI-Kruppel-type zinc finger
nuclear factor that is able to repress, activate, and initiate
transcription depending on promoter architecture and the cellular
environment (1, 2). For example, YY1 activates or represses the
c-fos promoter depending on the orientation of a YY1
recognition element in the promoter (3). YY1 switches between an
activator or repressor of the human papillomavirus type 18 promoter
depending on the integrity of a distinct element upstream in the
promoter (4). YY1 competes with nuclear factor- B for
overlapping binding sites in the serum amyloid A1 promoter, inhibits
promoter activity by passive means (5), and can antagonize the
interaction of serum response factor to overlapping binding sites in the actin promoter (6). YY1 functionally interacts with a
large number of key transcriptional regulators such as Sp1, c-Myc,
adenovirus E1A, the cAMP-response element-binding protein-related
factor, p300, and components of the general transcriptional apparatus
including the large subunit of RNA polymerase II and transcription
factor IIB (7-11). The capacity of YY1 to bend DNA when it binds the
promoter may help facilitate direct contact between regulatory
proteins. YY1 can interact with histone deacetylases to repress the
activity of certain promoters, including the human immunodeficiency
virus, type I long terminal repeat (12), thereby modulating histone and
chromatin structure.
The pathogenesis of common vascular disorders such as atherosclerosis
and restenosis after balloon angioplasty is believed to be mediated at
least in part by phenotypic changes involving smooth muscle cells of
the artery wall. These cells normally adopt a "contractile"
phenotype (13) in the vessel wall, but upon activation (such as
mechanical injury imparted by angioplasty), these cells become
"synthetic" (13) and contribute to developing lesions by migrating,
proliferating, producing extracellular matrix, and elaborating and
responding to myriad growth-regulatory molecules (14, 15). YY1 can
repress the promoters of a wide spectrum of pro-atherogenic genes,
including cytokines, hormones, and growth factors (16-21). However,
whether YY1 is even expressed in the artery wall or is regulated in the
adaptive response to injury is presently not known, nor is it known
whether YY1 can influence the growth of smooth muscle cells or other
cell types.
 |
EXPERIMENTAL PROCEDURES |
Cell Culture--
Primary rat aortic smooth muscle cells were
obtained from Cell Applications, Inc. (San Diego, CA) and cultured in
Waymouth's medium, pH 7.4, containing 10% fetal bovine serum, 10 units/ml penicillin, and 10 µg/ml streptomycin in a humidified
atmosphere of 5% CO2 at 37 °C. The cells were rendered
quiescent by incubation in Waymouth's medium, pH 7.4, containing
0.25% fetal bovine serum for 24 h. Cells were not used beyond
passage 7 in experiments. Additionally, normal medial vascular smooth
muscle cells were derived and characterized from coronary arteries of
patients undergoing cardiac transplantation for non-ischemic
cardiomyopathy and human atherosclerotic plaque vascular smooth muscle
cells from carotid endarterectomy specimens of patients with
symptomatic carotid disease. Cells were cultured to passage 2-4 before
isolation for nuclear extracts.
cDNA Array Analysis--
Differential gene expression
between injured and uninjured smooth muscle cells was assessed using
Atlas cDNA expression arrays (CLONTECH
Laboratories, Palo Alto, CA). Briefly, total RNA (15 µg) was treated
with RNase-free DNase I and then mRNA was isolated using a poly(A)
Quik mRNA isolation kit (Stratagene, La Jolla, CA). cDNA was
generated from equivalent amounts of mRNA, and
32P-labeled cDNAs were purified using Chromaspin-200
diethyl pyrocarbonate-water columns provided with the kit.
Probes with similar specific activities were hybridized separately to
two identical arrays under conditions specified by the manufacturer.
Hybridization signals were quantitated using ImageQuant software
(Amersham Pharmacia Biotech).
RT-PCR--
Total RNA was prepared from cells that were injured
(22) or exposed to FGF-2 with TRIzol in accordance with the
manufacturer's instructions (Life Technologies, Inc.). RNA was
reverse-transcribed to cDNA using oligo(dT) primers and Superscript
(Life Technologies, Inc.). PCR was performed using Platinum
Taq DNA polymerase (Life Technologies, Inc.) with the
following amplification conditions: 20 mM Tris-HCl, pH 8.4, 50 mM KCl, 1 mM MgCl2, 250 µM dNTP, 0.5 µM primers, 2 µl of
cDNA, and 1 unit of Platinum Taq DNA polymerase. For YY1 PCR, cycling conditions were 94 °C for 30 s, 30 cycles of 95 °C for 10 s; 53 °C for 30 s, and 72 °C for 1 min. For GAPDH RT-PCR, the same cycling conditions were used except for
an annealing temperature of 58 °C and a cycle number of 25. Primer
sequences for YY1 were YY1a5 (5'-GAAAACATCTGCACACCCACGGTCC-3') and
YY1a3 (5'-GTCCTCCTGTTGGGACCACAC-3'), whereas those of GAPDH are GAP5 (5'-ACCACAGTCCATGCCATCAC-3') and GAP3
(5'-TCCACCACCCTGTTGCTGTA-3'). Linearity of gene expression was
established by cycle-based RT-PCR in pilot experiments for both YY1 and
GAPDH.
Western Blot Analysis--
Lysates of cells injured or exposed
to FGF-2 were resolved by electrophoresis on denaturing 10%
SDS-polyacrylamide gels for 2 h at 100 V. After transfer of
proteins to Immobilon P nylon membranes (Millipore, Bedford, MA) and
blocking nonspecific binding sites with nonfat skim milk, membranes
were incubated with mouse monoclonal anti-peptide antibodies targeting
YY1 (Santa Cruz Biotechnology, Santa Cruz, CA) (1:1000) prior to
chemiluminescence detection (PerkinElmer Life Sciences).
Coomassie-stained gels were destained and photographed to confirm equal
loading. In FGF-2 antibody preincubation experiments, growth-quiescent
smooth muscle cells were incubated with neutralizing rabbit anti-human
FGF-2 antibodies or rabbit pre-immune IgG (100 µg/ml) for 1.5 h
prior to scraping and assessment of YY1 expression by Western blotting.
The FGF-2 antibody (AB-33-NA; R & D Systems) does not cross-react with
recombinant human (rh) FGF-4, rhFGF-5, rhFGF-6, rhFGF-7,
recombinant murine (rm) FGF-8b, rmFGF-8c, rhFGF-9, rfFGF-10,
rmFGF-15, rhFGF-17, or rhFGF-18 and has less than 5% reactivity with
FGF-1 (acidic) and rh -ECGF, based on direct enzyme-linked
immunosorbent assay by the manufacturer (R & D Systems).
Electrophoretic Mobility Shift Analysis--
Nuclear extracts of
cells injured (22) or exposed to FGF-2 were prepared as described
previously (23). Binding reactions were performed using 10 µg of
nuclear extract in 20 µl containing 1 µg of
poly(dI·dC)-poly(dI·dC) (Sigma), 12 mM HEPES, pH 7.9, 4 mM Tris-HCl, pH 7.9, 1 mM EDTA, 1 mM dithiothreitol, 12% glycerol, and the
32P-labeled Oligo MVYY1 (120,000 cpm) or
32P-labeled Oligo A for 35 min at 22 °C. In competition
or supershift experiments, the indicated molar excess of unlabeled
oligonucleotide or 2 µg of anti-peptide antibody (Santa Cruz
Biotechnology, Santa Cruz, CA) was included in the binding mixture 10 min prior to addition of the probe. Bound complexes were separated from
the unbound probe by non-denaturing 6% polyacrylamide gel
electrophoresis in 1× TBE running buffer at 100 V. The gels
were vacuum-dried and exposed to Hyperfilm-MP (Amersham Pharmacia
Biotech) overnight at 80 °C.
Rat Carotid Balloon Injury--
Male Sprague-Dawley rats
(450-550 g) were anesthetized with ketamine (60 mg/kg,
intraperitoneal) and xylazine (8 mg/kg, intraperitoneal), and the left
common and external carotid arteries were exposed via a midline neck
incision. A 2F Fogarty balloon catheter (Baxter Healthcare) was
introduced into the external carotid, advanced into the common carotid,
inflated to generate resistance, and withdrawn three times as described
previously (24). The catheter was withdrawn, and a ligature was applied
to the external carotid proximal to the arteriotomy. Animals were
sacrificed 4 h after injury by lethal injection of phenobarbitone
and perfusion-fixed using 10% (v/v) formaldehyde at 120 mm Hg. The
carotids were dissected free, washed with PBS, pH 7.4, placed in
OCT (Miles), and frozen in liquid nitrogen. Sections (5 µm)
were air-dried, fixed in acetone for 15 min, and then air-dried. The
sections were then exposed to 1% hydrogen peroxide for 20 min, rinsed
in PBS, pH 7.4, and incubated with 100 µl of YY1 antibodies (Santa
Cruz Biotechnology) (diluted 1:100 in 0.5% bovine serum albumin/PBS,
pH 7.4) for 45 min. The sections were washed with 0.5% Tween 20/PBS,
pH 7.4, followed by PBS, pH 7.4, alone and incubated with 100 µl of
biotinylated rabbit anti-mouse secondary antibody (Vector Laboratories)
diluted 1:300 in 0.5% bovine serum albumin for 30 min. The sections
were washed in PBS, pH 7.4, for 5 min prior to incubation in 100 µl of avidin-biotin complex (Vector Laboratories) diluted 1:100 in 0.5%
bovine serum albumin for 30 min. The sections were washed again in
Tween and PBS as above, and antigen-antibody complexes were detected in
3 min using the diaminobenzidine system. Sections were washed in PBS,
pH 7.4, counterstained with hematoxylin for 20 s, dehydrated,
cleared and mounted, and then visualized by light microscopy and photographed.
FGF-2 Immunoassay--
FGF-2 levels in the supernatant were
quantitated using the commercial enzyme-linked immunosorbent assay
Quantikine HS human FGF basic immunoassay (R & D Systems).
Transient Transfection Analysis--
Smooth muscle cells were
transiently transfected with 5 µg of the chloramphenicol
acetyltransferase reporter construct, (E1)4TK-CAT, using
FuGENE6 according to the manufacturer's instructions (Roche Molecular
Biochemicals). FGF-2 was incubated with growth-quiescent cells for
24 h. Chloramphenicol acetyltransferase activity was assessed as
described previously (23) and normalized to the concentration of
protein in the cell lysates (Bio-Rad protein assay).
YY1 Overexpression Proliferation Assay--
Smooth muscle cells
(rat aortic) or endothelial cells (bovine aortic) were grown to 60%
confluence in 96-well plates, incubated in serum-free medium for
24 h, and then transfected with the indicated amounts of either
pCB6+-YY1 or pCB6+ using FuGENE6, according to
the manufacturer's instructions, and incubated for 3 days in the
continuous presence of 5% fetal bovine serum. Plasmid transfection of
endothelial and smooth muscle cells with FuGENE6 is extremely efficient
(25). The cells were trypsinized, and suspensions were quantitated by
automated Coulter counter.
Northern Blot Analysis--
Total RNA was isolated from smooth
muscle cells or endothelial cells 24 h after transfection with 10 µg of either pCB6+-YY1 or pCB6+ using FuGENE6
and probed with 32P-labeled YY1 cDNA (generated by PCR
using the same primers described above) or [32P]GAPDH
cDNA in Northern blot analysis as described previously (22,
23).
Immunohistochemical Detection of YY1, p53, FGF-2, and PCNA in
Human Carotid Arteries--
Immunohistochemical analysis was performed
with antibodies to YY1 (sc-7341, final dilution 1:200; Santa Cruz
Biotechnology), p53 (DO-1, dilution 1:50; Immunotech), PCNA (PC10,
dilution 1:50; Dako), basic FGF (AB-33-NA, dilution 1:200; R & D
systems), and smooth muscle -actin (ASM-1, dilution 1:25;
Novocastra) on consecutive paraffin sections of formalin-fixed
atherosclerotic carotid artery specimens obtained by
endarterectomy at St. Vincent's Hospital, Sydney, NSW, Australia.
Prior to staining, deparaffinized sections were treated with 3%
hydrogen peroxide (peroxidase blocking) and boiled in citrate buffer,
pH 6.0, to retrieve antigenicity. The standard avidin-biotin complex
immunoperoxidase technique was used (26). After washing in
Tris-buffered saline, pH 7.6, sections were incubated in the primary
antibody for 60 min, followed by incubation with the appropriate
secondary antibody (horse anti-mouse, Vector BA-2000 or goat
anti-rabbit, Vector BA-1000) for 20 min, and finally with avidin-biotin
complex (Elite Vector PK-6100) for 30 min. Immunogenicity was
visualized by treatment in 3,3'-diaminobenzidine solution for 2 min,
which produced brown coloration. Sections were counterstained with
Mayer's hematoxylin. As negative control, the primary antibody was
omitted, or the sections were treated with the immunoglobulin fraction
of suitable non-immune serum as a substitute for the primary antibody.
No positive staining was observed in any of the negative control
sections (data not shown).
 |
RESULTS AND DISCUSSION |
YY1 Expression and Binding Activity Is Induced in Smooth Muscle
Cells in Response to Injury--
In efforts to identify new genes that
are activated following mechanical injury in vascular smooth muscle
cells, we reverse-transcribed mRNA isolated from
mechanically injured and uninjured growth-quiescent aortic smooth
muscle cells and compared the expression of specific genes by
hybridization with spatially addressable cDNA arrays. We
demonstrated previously that the immediate-early gene and transcription factor early growth response factor-1 (Egr-1) is rapidly induced by
injury using a well established in vitro scraping model
(24). YY1 transcript levels, like those of Egr-1, increased severalfold within 1 h of injury (Fig.
1A). In contrast, -tubulin
mRNA expression did not change in response to injury.

View larger version (59K):
[in this window]
[in a new window]
|
Fig. 1.
YY1 is inducibly expressed in
growth-quiescent vascular smooth muscle cells following mechanical
injury. A, growth-arrested smooth muscle cells
were injured by scraping repeatedly with a sterile stainless steel comb
or left undisturbed, and total RNA was isolated after 1 h.
Reverse-transcribed 32P-labeled cDNA was hybridized to
cDNA array filters (CLONTECH) prior to washing,
vacuum drying, and quantitation of signal intensity by PhosphorImager
analysis (ImageQuant, Molecular Dynamics). Data was normalized to
levels of -tubulin signals between injured and uninjured samples.
B, inducible YY1 mRNA and protein expression at various
times after injury as assessed by reverse-transcription PCR
(upper panel) and Western blot (lower panel)
analysis, respectively. GAPDH expression and the Coomassie-stained gel
indicate unbiased loading. C, EMSA using
32P-Oligo MVYY1 or 32P-Oligo A bearing
consensus binding sites for YY1 and Egr-1, respectively. Nuclear
extracts were prepared from quiescent smooth muscle cells injured and
then left for various times. The gels were vacuum-dried and radioactive
signals were visualized by autoradiography overnight at 80 °C.
D, competition analysis. Nuclear extracts prepared from
cells 2 h after injury were incubated with the indicated -fold
molar excesses of unlabeled Oligo MVYY1 or Oligo A for 10 min prior to
the addition of 32P-Oligo MVYY1 or 32P-Oligo A. E, specificity analysis. Nuclear extracts prepared from
cells 2 h after injury were incubated with 2 µg of monoclonal
antibodies targeting YY1 or Egr-1 for 10 min prior to the addition of
the radiolabeled probe. Uninj denotes nuclear extracts
prepared from uninjured cells. Radioactivity at the bottom
of the gel shows free probe; the probe was run off the gel
in C (left panel). The sequence of Oligo MVYY1 is
5'-TGCCTTGCAAAATGGCGTTACTGCAG-3' (sense strand), and Oligo A is
5'-GGGGGGGGCGGGGGCGGGGGCGGGGGAGGG-3' (sense strand). F, YY1
protein is expressed in the carotid artery wall following balloon
injury. Right common carotid arteries of male Sprague-Dawley rats were
injured by multiple inflations of a 2F embolectomy balloon prior to
sacrifice of the animals 4 h after injury. Sections (5 µm) were
stained for YY1 immunoreactivity using monoclonal YY1 antibodies,
rabbit ant-mouse antibodies, and chemiluminescence detection. The
lowest panel shows lack of specific signal when the primary
antibody (1°) is omitted.
|
|
We next performed RT-PCR analysis using primers directed to elements
within the coding region to confirm that YY1 mRNA is inducibly
expressed following mechanical injury. YY1 was basally expressed in
uninjured smooth muscle cells (Fig. 1B, upper
panel). Injury increased YY1 expression within 2 h of injury,
and levels remained elevated after 4 h. Western immunoblot
analysis using monoclonal antibodies targeting YY1 produced a single
protein species with a relative molecular mass of 68 kDa, which
corresponds to the expected molecular mass of YY1 (Fig. 1B,
lower panel) (21). YY1 protein, like YY1 mRNA (Fig. 1,
A and B, upper panel), was basally
expressed, and levels were increased upon mechanical injury (Fig.
1B, lower panel).
To determine whether changes in YY1 mRNA and protein expression
after mechanical injury correlate with the binding activity of this
transcription factor, we performed electrophoretic mobility shift
analysis (EMSA) using 32P-labeled Oligo MVYY1, a
double-stranded oligonucleotide bearing consensus binding element for
YY1 from the upstream conserved region of the Moloney murine leukemia
gene. A major nucleoprotein complex of weak intensity was detected
using nuclear extracts of uninjured cells (Fig. 1C,
left panel, large arrow). The intensity of this
complex increased significantly within 1 h of injury, and levels
remained high after 4 h (Fig. 1C, left
panel). To confirm the integrity of these extracts, we performed
EMSA using 32P-labeled Oligo A, whose sequence derives from
the proximal PDGF-A promoter and contains overlapping consensus binding
elements for Egr-1. Egr-1 binding activity increased within 1 h of
injury (Fig. 1C, right panel), as demonstrated
previously in vascular endothelial cells (27) and consistent with Fig.
1A.
To demonstrate the specificity of the nucleoprotein complex obtained
using 32P-Oligo MVYY1, we incubated the extracts with
increasing amounts of unlabeled oligonucleotide. This resulted in
dose-dependent inhibition of the inducible complex and
virtually complete inhibition at a 25-fold excess (Fig. 1D,
arrow). In contrast, the same -fold excess of unlabeled
Oligo A had no effect of the intensity of this complex. To elucidate
the identity of the protein component of the inducible complex, we
performed supershift analysis. Incubation of the nuclear extracts with
YY1 antibodies used for Western blot analysis prior to the addition of
32P-Oligo MVYY1 eliminated the formation of the complex,
instead producing a supershift (Fig. 1E). In contrast, when
an identical amount of Egr-1 antibodies was used for preincubation, the
complex was completely unaffected. These data provide the first
demonstration that YY1 mRNA and protein are increased in vascular
smooth muscle cells upon mechanical injury.
YY1 Expression Induced in Balloon-injured Rat Carotid
Arteries--
To determine whether the induction of YY1 by mechanical
injury in vitro is also observed following injury to the
intact vessel wall, we performed balloon angioplasty to the left common
carotid arteries of Sprague-Dawley rats. Immunohistochemical analysis with YY1 antibodies revealed that YY1 is weakly expressed by smooth muscle cells in the medial compartment of the artery wall (Fig. 1F, top panel). The intensity of staining
increased significantly in the media within 4 h of balloon
injury (Fig. 1F, middle panel). The specificity
of staining is evident by our inability to observe YY1 signal when
primary (YY1) antibody was omitted from the protocol (Fig.
1F, bottom panel). These data demonstrate for the
first time the induction of YY1 in the injured artery wall.
FGF-2 Stimulates YY1 Expression, Binding, and Transcriptional
Activity--
We hypothesized that the activation of YY1 following
injury is regulated by endogenous factors released from the cells
themselves. We focused on FGF-2, because FGF-2 mRNA and protein are
basally expressed in vascular smooth cells in culture, as well as in
the intact artery wall (28). We measured levels of FGF-2 in the supernatant of cultured growth-quiescent smooth muscle cells by enzyme-linked immunosorbent assay before and after scraping.
Immunoreactive FGF-2 was barely detectable in the culture medium or
supernatant of undisturbed smooth muscle cells (Fig.
2A). However, FGF-2 levels increased dramatically within 2 min of injury (Fig. 2A).
This led us to explore the possibility that FGF-2 may regulate the expression of YY1, hitherto unreported in any cell type.

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 2.
FGF-2 stimulates YY1 expression, binding, and
transcriptional activity in growth-quiescent vascular smooth muscle
cells. A, endogenous FGF-2 is released from
growth-quiescent vascular smooth muscle cells within minutes of
scraping. FGF-2 levels in the culture medium were measured (before and
2 min after scraping) using a commercial enzyme-linked immunosorbent
assay specific for FGF-2. (Quantikine, R & D Systems) and recombinant
FGF-2 as the standard. Smooth muscle cells were exposed to FGF-2 for
various times prior to (B) isolation of total RNA for RT-PCR
analysis, extraction of nuclear extracts for (C) Western
blot analysis using YY1 antibodies, or (D)
immunofluorescence detection using YY1 antibodies (Ab).
E, EMSA using 32P-Oligo MVYY1 or
32P-Oligo A probe and nuclear extracts of smooth muscle
cells exposed to FGF-2 for various times. Radioactivity at the
bottom of the gel shows free probe; the probe was
run off the gel in E, left panel. The sequence of
Oligo MVYY1 and Oligo A is shown in the legend to Fig. 1. F,
transient transfection analysis in smooth muscle cells harboring
reporter plasmid (E1)4TK-CAT exposed to various
concentrations of FGF-2 for 24 h. Uninj or
Untrd denotes extracts prepared from uninjured or untreated
cells, respectively. GAPDH expression and the Coomassie-stained gel
indicate unbiased loading. bp, base pairs. CAT,
chloramphenicol acetyltransferase.
|
|
YY1 mRNA expression increased in vascular smooth muscle cells
exposed to FGF-2. RT-PCR analysis revealed that YY1 transcript levels
increased within 1 h of exposure to the growth factor and remained
elevated even after 24 h (Fig. 2B). Western immunoblot analysis confirmed these findings of inducible YY1 expression at the
level of protein (Fig. 2C).
To address the spatial distribution of inducible YY1 protein expression
we performed in situ immunofluorescence analysis using YY1
antibodies as the primary antibody with secondary antibodies tagged
with fluorescein isothiocyanate. YY1 immunoreactivity was preferentially detected in the nuclei of a small proportion of smooth
muscle cells (Fig. 2D). After 1 or 4 h of exposure to
FGF-2, a considerably greater proportion of cell nuclei showed
immunofluorescence for YY1 protein. The specificity of the system was
confirmed by the inability to detect immunofluorescence when the YY1
antibody was omitted (Fig. 2D).
We next used EMSA to demonstrate whether FGF-2-inducible YY1 expression
protein produced increased DNA binding activity. FGF-2 increased YY1
DNA binding activity within 1 h, and levels remained elevated
after 4 h (Fig. 2E, left panel), similar to
our earlier observations using nuclear extracts of cells that had been
injured (Fig. 1C, left panel). Unlike the rapid
transient induction of Egr-1 after injury (Fig. 1C,
right panel), however, Egr-1 binding activity was more
sustained in cells exposed to FGF-2 (Fig. 2E, right
panel).
To demonstrate that YY1 binding activity induced by FGF-2 was
functionally significant, we exposed smooth muscle cells transfected with the chloramphenicol acetyltransferase-based reporter construct (E1)4TK-CAT, which contains four copies of a high affinity
YY1 binding site upstream of the thymidine kinase promoter (24), to
FGF-2. This construct has previously been used to gauge YY1 binding
activity in an overexpression setting in fibroblasts (24). FGF-2
stimulated chloramphenicol acetyltransferase reporter expression within
24 h in a dose-dependent manner (Fig. 2F).
Taken together, these findings demonstrate that FGF-2 induces YY1
mRNA and protein expression, DNA-binding activity, and can
transactivate gene expression in vascular smooth muscle cells.
YY1 Induction by Injury Is Mediated by FGF-2 Release--
Because
injury causes the rapid release of FGF-2 from smooth muscle cells, and
injury and recombinant FGF-2 each stimulate YY1 expression in this cell
type, we finally determined whether the inducible expression of YY1
following injury is mediated by the local effect of endogenous FGF-2.
We therefore incubated growth-quiescent smooth muscle cells with
neutralizing FGF-2 antibodies prior to scraping and then assessed YY1
levels by Western immunoblot analysis. Injury increased YY1 protein
levels within 2 h (Fig. 3).
Interestingly, levels of the transcription factor were significantly
reduced in the lysates of cells preincubated with antibodies to FGF-2 (Fig. 3). In contrast, isotype- and species-matched immunoglobulin has
no appreciable effect on injury-inducible YY1 protein expression (Fig.
3). These findings demonstrate the paracrine effect of endogenous FGF-2
in the increased expression of YY1 in smooth muscle cells following
mechanical injury.

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 3.
YY1 induction by injury is due to paracrine
activity of endogenous FGF-2. Growth-quiescent human smooth muscle
cells were incubated with neutralizing rabbit anti-human FGF-2
antibodies or rabbit pre-immune IgG (100 µg/ml) for 1.5 h prior
to scraping and assessment of YY1 expression by Western blot analysis.
Uninj denotes extracts prepared from uninjured cells. The
Coomassie-stained gel indicates unbiased loading.
|
|
Overexpression of YY1 Suppresses Cellular
Proliferation--
Because YY1 can repress the expression of growth
factor genes, we determined whether YY1 could influence smooth muscle
cell replication. Incubation of sub-confluent growth-quiescent smooth muscle cells in medium containing serum, as expected, stimulated proliferation in this population. Cells transfected with 0.5 or 1 µg
of a cytomegalovirus-driven YY1 expression vector,
pCB6+-YY1, strongly inhibited proliferation relative to its
empty vector (pCB6+) control (Fig.
4). We used Northern blot analysis to
demonstrate that YY1 was indeed expressed in the smooth muscle cells
following pCB6+-YY1 transfection. This showed strong
expression of the exogenous YY1 mRNA within 24 h of transfection
(Fig. 5). These findings indicate that
YY1 is a potent inhibitor of vascular smooth muscle cell proliferation.
In contrast, proliferation of vascular endothelial cells was not
influenced as a consequence of transfection with identical amounts of
YY1 (see Fig. 4 and Fig. 5), thus indicating the cell-specific nature
of inhibition by YY1. To date, YY1 has not been directly linked to cell
replication in any cell type.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 4.
YY1 inhibits vascular smooth muscle cell
proliferation but has no effect on endothelial cell proliferation.
Subconfluent growth-quiescent rat aortic smooth muscle cells
(SMC) or bovine aortic endothelial cells (EC) in
96-well plates were transfected with the indicated amounts of either
pCB6+-YY1 or pCB6+ using FuGENE6. The cells
were trypsinized, and suspensions were quantitated using an automated
Coulter counter after 3 days in the continuous presence of 5% fetal
bovine serum.
|
|

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 5.
Overexpression of YY1 mRNA in smooth
muscle cells and endothelial cells transfected with
YY1-pCB6+. Subconfluent growth-quiescent rat aortic
smooth muscle cells (SMC) or bovine aortic endothelial cells
(EC) in 100-mm plates were transfected with 10 µg of
pCB6+-YY1 or pCB6+ using FuGENE6. Northern blot
analysis was performed on total RNA isolated from the cells 24 h
after transfection.
|
|
YY1 and FGF-2 Expression in Human Atherosclerotic
Tissue--
Because FGF-2 positively regulates YY1 expression, we
hypothesized that YY1 and FGF-2 would colocalize in the arterial wall. Immunohistochemical staining revealed that YY1 was strongly expressed by -actin-positive smooth muscle cells in the arterial media compared with weak expression in the intima (Fig.
6). YY1 staining in the media was
distributed mosaically and was exclusively nuclear. In contrast, p53
was expressed in the intima. FGF-2 immunoreactivity was detected in the
nuclear and cytoplasmic compartments of medial smooth muscle cells,
consistent with previous observations in fibrous lesions (29, 30).
FGF-2 immunoreactivity was coincident with YY1 expression (Fig. 6).
Finally, we reasoned that because YY1 inhibits smooth muscle cell
replication (Fig. 4), YY1 expression in the artery wall would inversely
correlate with mitogenicity. PCNA staining was accordingly confined to
smooth muscle cells and occasional macrophages in the intima, with few
PCNA-expressing cells detected in the media (Fig. 6).

View larger version (131K):
[in this window]
[in a new window]
|
Fig. 6.
YY1 and FGF-2 are preferentially expressed by
smooth muscle cells in the human carotid media.
Immunohistochemical staining for -actin, YY1, p53, FGF-2, and PCNA
is indicated in the figure. Smooth muscle cells are larger and
elongated in the media compared with smooth muscle cells in the intima,
which have irregular shape. The data presented in the figure is
representative of three patients.
|
|
The mechanisms governing the activation of the YY1 gene expression are
presently unknown. In smooth muscle cells, YY1 has been found to
physically associate with (31) and activate the smooth muscle
cell-specific SMC22- promoter (32) but has not yet been reported to
be induced by defined extracellular stimuli in this cell type. YY1
repressor activity is induced in cardiac myocytes exposed to
interleukin-1 (33) and in osteosarcoma cells incubated with vitamin D
(11). The human YY1 promoter sequence cloned from a liver genomic
library contains a single transcriptional initiation site located 478 base pairs upstream of the AUG translational start motif (34). Among
several putative nucleotide recognition elements for known
transcriptional regulators is a consensus site for cAMP-response
element-binding protein/activating transcription factor and
three tandem sites for Myb. cAMP-response element-binding protein can
mediate transcriptional activation by FGF-2 (35). Similarly, FGF-2 can
stimulate the expression of Myb factors (36), which can potentiate
FGF-inducible proliferation (37). Therefore, our present demonstration
of increased YY1 expression in smooth muscle cells exposed to FGF-2 may
be because of the activity of these positive regulatory transcription
factors. The spatial relationship established between FGF-2 and YY1 in
lesions in this paper may be representative of other settings.
Interestingly, FGF-2 and other members of the FGF family are expressed
in the early stages of embryonic development (38), consistent
with peri-implantation lethality in mice deficient in YY1 gene
(39).
We observed approximately a 3-fold increase in YY1 mRNA and protein
expression, as well as DNA binding and transcriptional activity with
FGF-2. This magnitude induction may be sufficient to influence gene
expression at local sites of FGF-2 release in the vasculature. Indeed,
as little as a 2-fold induction in endogenous YY1 expression can lead
to significant transcriptional repression in cardiac myocytes, which is
entirely dependent on the integrity of the zinc finger structure of YY1
(33). In other contexts, minor changes in DNA binding activity can have
profound effects on the transcriptional activity of dependent genes
(40).
This study demonstrates that local FGF-2 release can facilitate both
positive and negative influences at the level of transcription. We
demonstrated previously that FGF-2 induces the expression of Egr-1,
which activates the expression of many genes implicated in the
initiation and progression of atherosclerosis and restenosis (22). In
vascular endothelial cells, the induction of Egr-1 after injury is
blocked by antibodies targeting FGF-2 (27). Thus, FGF-2 can stimulate
the expression of two very different kinds of transcription factors,
namely YY1 (the repressor) and Egr-1 (the activator) in the context of
smooth muscle cell injury. It is the complex interplay of transcription
factors at promoter elements that dictate gene expression and changes
in cell movement, proliferation, and adhesion in the injured vessel wall.
We demonstrate here for the first time that YY1 expression and DNA
binding activity increase in vascular smooth muscle cells within hours
of mechanical injury. We have also shown that FGF-2 is a positive
regulator of YY1 expression and moreover that endogenous FGF-2 accounts
for the induction of YY1 after injury. The present study demonstrates
the yin yang nature of YY1. On the one hand, YY1 expression is under
the direct control of FGF-2, which stimulates smooth muscle cell
growth. On the other hand, YY1 can inhibit smooth muscle cell growth.
That YY1 and FGF-2 are coexpressed in growth-quiescent smooth muscle
cells in human arteries suggests that YY1 may restrict pro-atherogenic
gene expression and cell growth in the injured vessel wall. Because the
adaptive response to arterial cell injury involves a dramatic increase
in smooth muscle cell replication, the sustained activation of this
enigmatic transcription factor may help restrict what otherwise may
result in greater smooth muscle cell mitogenesis in early
atherogenesis. Moreover, that YY1 inhibits the growth of smooth muscle
cells without influencing endothelial cell proliferation suggests that strategies forcing the expression of exogenous YY1 in the injured vessel wall could be useful to inhibit intimal thickening without affecting re-endothelialization and the re-establishment of a non-thrombogenic surface.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Michael L. Atchison
(University of Pennsylvania, Philadelphia, PA) for the generous gift of
constructs (E1)4TK-CAT and pCB6+-YY1 and their backbones.
 |
FOOTNOTES |
*
This work was supported in part by grants from the National
Heart Foundation of Australia, National Health and Medical Research Council (NHMRC) of Australia, and New South Wales State Department of
Health. H. C. L. was supported by a postgraduate medical research scholarship from the NHMRC. L. M. K. was supported by a research fellowship from the NHMRC of Australia.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Center for
Thrombosis and Vascular Research, School of Pathology, The University of New South Wales, Sydney, NSW 2052, Australia. Tel.: 61-2-9385-2537; Fax: 61-2-9385-1389; E-mail: L.Khachigian@unsw.edu.au.
Published, JBC Papers in Press, August 3, 2001, DOI 10.1074/jbc.M104913200
 |
ABBREVIATIONS |
The abbreviations used are:
YY1, Yin
Yang-1;
RT-PCR, reverse transcribed polymerase chain reaction;
FGF, fibroblast growth factor;
GAPDH, glyceraldehyde-3-phosphate
dehydrogenase;
rh, recombinant human;
PBS, phosphate-buffered saline;
Egr, early growth response factor;
EMSA, electrophoretic mobility shift
analysis;
PCNA, proliferating cell nuclear antigen.
 |
REFERENCES |
| 1.
|
Shi, Y.,
Seto, E.,
Chang, L. S.,
and Shenk, T.
(1991)
Cell
67,
377-388
|
| 2.
|
Shrivastava, A.,
and Calame, K.
(1994)
Nucleic Acids Res.
22,
5151-5155
|
| 3.
|
Natesan, S.,
and Gilman, M. Z.
(1993)
Genes Dev.
7,
2497-2509
|
| 4.
|
Bauknecht, T.,
Jundt, F.,
Herr, I.,
Oehler, T.,
Delius, H.,
Shi, Y.,
Angel, P.,
and Zur Hausen, H.
(1995)
J. Virol.
69,
1-12
|
| 5.
|
Lu, S. Y.,
Rodriguez, M.,
and Liao, W. S.
(1994)
Mol. Cell. Biol.
14,
6253-6263
|
| 6.
|
Gualberto, A.,
LePage, D.,
Pons, G.,
Mader, S. L.,
Park, K.,
Atchison, M. L.,
and Walsh, K.
(1992)
Mol. Cell. Biol.
12,
4209-4214
|
| 7.
|
Lee, J. S.,
See, R. H.,
Galvin, K. M.,
Wang, J.,
and Shi, Y.
(1995)
Nucleic Acids Res.
23,
925-931
|
| 8.
|
Lee, J. S.,
Galvin, K. M.,
See, R. H.,
Eckner, R.,
Livingston, D.,
Moran, E.,
and Shi, Y.
(1995)
Genes Dev.
9,
1188-1198
|
| 9.
|
Seto, E.,
Lewis, B.,
and Shenk, T.
(1993)
Nature
365,
462-464
|
| 10.
|
Lee, J.-S.,
Galvin, K. M.,
and Shi, Y.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
6145-6149
|
| 11.
|
Guo, B.,
Aslam, F.,
van Wijnen, A. J.,
Roberts, S. G.,
Frenkel, B.,
Green, M. R.,
DeLuca, H.,
Lian, J. B.,
Stein, G. S.,
and Stein, J. L.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
121-126
|
| 12.
|
Coull, J. J.,
Romerio, F.,
Sun, J.-M.,
Volker, J. L.,
Galvin, K. M.,
Davie, J. R.,
Shi, Y.,
Hansen, U.,
and Margolis, D. M.
(2000)
J. Virol.
74,
6790-6799
|
| 13.
|
Campbell, G. R.,
and Campbell, J. H.
(1985)
Exp. Mol. Pathol.
42,
139-162
|
| 14.
|
Ross, R.
(1993)
Nature
362,
801-809
|
| 15.
|
Ross, R.
(1999)
N. Engl. J. Med.
340,
115-126
|
| 16.
|
Ye, J.,
Zhang, X.,
and Dong, Z.
(1996)
Mol. Cell. Biol.
16,
157-167
|
| 17.
|
Ye, J.,
Cippitelli, M.,
Dorman, L.,
Ortaldo, J. R.,
and Young, H. A.
(1996)
Mol. Cell. Biol.
16,
4744-4753
|
| 18.
|
Ye, J.,
Young, H. A.,
Zhang, X.,
Castranova, V.,
Vallyathan, V.,
and Shi, X.
(1999)
J. Biol. Chem.
274,
26661-26667
|
| 19.
|
Schwenger, G. T.,
Fournier, R.,
Hall, L. M.,
Sanderson, C. J.,
and Mordvinov, V. A.
(1999)
J. Allergy Clin. Immunol.
104,
820-827
|
| 20.
|
Park, K. Y.,
and Roe, J. H.
(1996)
Biochem. Biophys. Res. Commun
228,
745-751
|
| 21.
|
Fang, Y.,
and Sheffield, L. G.
(1998)
J. Mol. Endocrinol.
20,
337-344
|
| 22.
|
Khachigian, L. M.,
Lindner, V.,
Williams, A. J.,
and Collins, T.
(1996)
Science
271,
1427-1431
|
| 23.
|
Khachigian, L. M.,
Williams, A. J.,
and Collins, T.
(1995)
J. Biol. Chem.
270,
27679-27686
|
| 24.
|
Clowes, A. W.,
Reidy, M. A.,
and Clowes, M. M.
(1983)
Lab. Invest.
49,
327-333
|
| 25.
|
Khachigian, L. M.,
Santiago, F. S.,
Rafty, L. A.,
Chan, O. L. W.,
Delbridge, G. J.,
Bobik, A.,
Collins, T.,
and Johnson, A. C.
(1999)
Circ. Res.
84,
1258-1267
|
| 26.
|
Hsu, S.-M.,
Raine, L.,
and Fanger, H.
(1981)
J. Histochem. Cytochem.
29,
577-580
|
| 27.
|
Santiago, F. S.,
Lowe, H. C.,
Day, F. L.,
Chesterman, C. N.,
and Khachigian, L. M.
(1999)
Am. J. Pathol.
154,
937-944
|
| 28.
|
Lindner, V.,
and Reidy, M. A.
(1993)
Circ. Res.
73,
589-595
|
| 29.
|
Hughes, S. E.,
Crossman, D.,
and Hall, P. A.
(1993)
Cardiovasc. Res.
27,
1214-1219
|
| 30.
|
Brogi, E.,
Winkles, J. A.,
Underwood, R.,
Clinton, S. K.,
Alberts, G. F.,
and Libby, P.
(1993)
J. Clin. Invest.
92,
2408-2418
|
| 31.
|
Kim, S.,
Ip, H. S.,
Lu, M. M.,
Clendenin, C.,
and Paracek, M. S.
(1997)
Mol. Cell. Biol.
17,
2266-2278
|
| 32.
|
Jain, M.,
Layne, M. D.,
Watanabe, M.,
Chin, M. T.,
Feinberg, M. W.,
Sibinga, N. E. S.,
Hseih, C.-M.,
Yet, S.-F.,
Stemple, D. L.,
and Lee, M. E.
(1998)
J. Biol. Chem.
273,
5993-5996
|
| 33.
|
Patten, M.,
Wang, W.,
Aminololama-Shakeri, S.,
Burson, M.,
and Long, C. S.
(2000)
J. Mol. Cell. Cardiol.
32,
1341-1352
|
| 34.
|
Yao, Y.-L.,
DuPont, B. R.,
Ghosh, S.,
Fang, Y.,
Leach, R. J.,
and Seto, E.
(1998)
Nucleic Acids Res.
26,
3776-3783
|
| 35.
|
Tan, Y.,
Rouse, J.,
Zhang, A.,
Cariati, S.,
Cohen, P.,
and Comb, M. J.
(1996)
EMBO J.
15,
4629-4642
|
| 36.
|
Marhamati, D. J.,
Bellas, R. E.,
Arsura, M.,
Kypreos, K. E.,
and Sonenshein, G. E.
(1997)
Mol. Cell. Biol.
17,
2448-2457
|
| 37.
|
Turque, N.,
Plaza, S.,
Klemphauer, K.-H.,
and Saule, S.
(1997)
J. Virol.
71,
9778-9781
|
| 38.
|
Jung, J.,
Zheng, M.,
Goldfarb, M.,
and Zaret, K. S.
(1999)
Science
284,
1998-2003
|
| 39.
|
Donohoe, M. E.,
Zhang, X.,
McGinnis, L.,
Biggers, J.,
Li, E.,
and Shi, Y.
(1999)
Mol. Cell. Biol.
19,
7237-7244
|
| 40.
|
Hahn, C. N.,
Kerry, D. M.,
Omdahl, J. L.,
and May, B. K.
(1994)
Nucleic Acids Res
22,
2410-2416
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. T. Chin
ATF-4 and Vascular Injury: Integration of Growth Factor Signaling and the Cellular Stress Response
Circ. Res.,
August 15, 2008;
103(4):
331 - 333.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. P. Malabanan, P. Kanellakis, A. Bobik, and L. M. Khachigian
Activation Transcription Factor-4 Induced by Fibroblast Growth Factor-2 Regulates Vascular Endothelial Growth Factor-A Transcription in Vascular Smooth Muscle Cells and Mediates Intimal Thickening in Rat Arteries Following Balloon Injury
Circ. Res.,
August 15, 2008;
103(4):
378 - 387.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Y. Tan, V. C. Midgley, M. M. Kavurma, F. S. Santiago, X. Luo, R. Peden, R. G. Fahmy, M. C. Berndt, M. P. Molloy, and L. M. Khachigian
Angiotensin II-Inducible Platelet-Derived Growth Factor-D Transcription Requires Specific Ser/Thr Residues in the Second Zinc Finger Region of Sp1
Circ. Res.,
February 29, 2008;
102(4):
e38 - e51.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Aikawa
The Balance of Power: The Law of Yin and Yang in Smooth Muscle Cell Fate: Is YY1 a Vascular Protector?
Circ. Res.,
July 20, 2007;
101(2):
111 - 113.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. S. Santiago, H. Ishii, S. Shafi, R. Khurana, P. Kanellakis, R. Bhindi, M. J. Ramirez, A. Bobik, J. F. Martin, C. N. Chesterman, et al.
Yin Yang-1 Inhibits Vascular Smooth Muscle Cell Growth and Intimal Thickening by Repressing p21WAF1/Cip1 Transcription and p21WAF1/Cip1-Cdk4-Cyclin D1 Assembly
Circ. Res.,
July 20, 2007;
101(2):
146 - 155.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Kawai-Kowase and G. K. Owens
Multiple repressor pathways contribute to phenotypic switching of vascular smooth muscle cells
Am J Physiol Cell Physiol,
January 1, 2007;
292(1):
C59 - C69.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-T. Ong, H.-T. Cheng, L.-W. Chang, T. Ohtsuka, R. Kageyama, G. D. Stormo, and R. Kopan
Target Selectivity of Vertebrate Notch Proteins: COLLABORATION BETWEEN DISCRETE DOMAINS AND CSL-BINDING SITE ARCHITECTURE DETERMINES ACTIVATION PROBABILITY
J. Biol. Chem.,
February 24, 2006;
281(8):
5106 - 5119.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Skaletz-Rorowski, H. Eschert, J. Leng, B. Stallmeyer, J. R. Sindermann, E. Pulawski, and G. Breithardt
PKC {delta}-induced activation of MAPK pathway is required for bFGF-stimulated proliferation of coronary smooth muscle cells
Cardiovasc Res,
July 1, 2005;
67(1):
142 - 150.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Baumeister, S. Luo, W. C. Skarnes, G. Sui, E. Seto, Y. Shi, and A. S. Lee
Endoplasmic Reticulum Stress Induction of the Grp78/BiP Promoter: Activating Mechanisms Mediated by YY1 and Its Interactive Chromatin Modifiers
Mol. Cell. Biol.,
June 1, 2005;
25(11):
4529 - 4540.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B.R. Wamhoff, M.H. Hoofnagle, A. Burns, S. Sinha, O.G. McDonald, and G.K. Owens
A G/C Element Mediates Repression of the SM22{alpha} Promoter Within Phenotypically Modulated Smooth Muscle Cells in Experimental Atherosclerosis
Circ. Res.,
November 12, 2004;
95(10):
981 - 988.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. S. Santiago and L. M. Khachigian
Ets-1 Stimulates Platelet-Derived Growth Factor A-Chain Gene Transcription and Vascular Smooth Muscle Cell Growth via Cooperative Interactions With Sp1
Circ. Res.,
September 3, 2004;
95(5):
479 - 487.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. J. Gordon, S. Saleque, and B. K. Birshtein
Yin Yang 1 Is a Lipopolysaccharide-Inducible Activator of the Murine 3' Igh Enhancer, hs3
J. Immunol.,
June 1, 2003;
170(11):
5549 - 5557.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. M. Kavurma, Y. Bobryshev, and L. M. Khachigian
Ets-1 Positively Regulates Fas Ligand Transcription via Cooperative Interactions with Sp1
J. Biol. Chem.,
September 20, 2002;
277(39):
36244 - 36252.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. M. Khachigian, R. G. Fahmy, G. Zhang, Y. V. Bobryshev, and A. Kaniaros
c-Jun Regulates Vascular Smooth Muscle Cell Growth and Neointima Formation after Arterial Injury. INHIBITION BY A NOVEL DNA ENZYME TARGETING c-Jun
J. Biol. Chem.,
June 14, 2002;
277(25):
22985 - 22991.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|